Fusion Pharmaceuticals (Fusion Pharmaceuticals) Interest Expense : $-5.80 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fusion Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Fusion Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ -1.85 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.80 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Fusion Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ -35.86 Mil. Fusion Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ -1.85 Mil. Fusion Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fusion Pharmaceuticals Interest Expense Historical Data

The historical data trend for Fusion Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Pharmaceuticals Interest Expense Chart

Fusion Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.80

-5.17

Fusion Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-1.22	-1.28	-1.33	-1.34	-1.85

Fusion Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.80 Mil.

Fusion Pharmaceuticals (NAS:FUSN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fusion Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $-1.85 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-35.86 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $60.26 Mil.

Fusion Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Fusion Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Pharmaceuticals Inc (NAS:FUSN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

270 Longwood Road South, Hamilton, ON, CAN, L8P 0A6

Website

https://www.fusionpharma.com

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.

Executives

Teresa Marie Bitetti	director	40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Bender	director	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Dmitri Bobilev	officer: Chief Medical Officer	C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
John Valliant	director, officer: Chief Executive Officer	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6
Christopher P Leamon	officer: Chief Scientific Officer	C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110
Mohit Rawat	officer: President and CBO	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6
Donald A Bergstrom	director	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philina Lee	director	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
John J Crowley	officer: Chief Financial Officer	251 BALLARDVALE STREET, WILMINGTON MA 01887
Healthcap Vii, L.p.	10 percent owner	18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018
James J O'leary	officer: Chief Medical Officer	830 WINTER STREET, WALTHAM MA 02452